Ten-Year Results of Intensity-Modulated Radiotherapy for T4 Nasopharyngeal Carcinoma: New Insight into the Value of Concurrent Chemotherapy

F. F. Kong,R. P. Zhai,J. Huang,L. L. Ye,R. W. Oei,C. Du,H. M. Ying,C. Hu
DOI: https://doi.org/10.1016/j.ijrobp.2020.07.379
2020-01-01
Abstract:To evaluate the long-term survival outcomes and toxicities of intensity-modulated radiotherapy (IMRT) with or without chemotherapy for patients with T4 nasopharyngeal carcinoma (NPC). Between September 2007 and January 2013, 155 patients with T4 NPC treated with intensity-modulated radiotherapy (IMRT) were retrospectively reviewed. The survival rate was calculated using the Kaplan-Meier method. The log-rank test was used to assess differences between survival curves. Adverse events were graded according to National Cancer Institute Common Toxicity Criteria version 4.02. With a median follow-up of 95 months, the estimated 10-yearlocal recurrent–free survival (LRFS), regional recurrent–free survival (RRFS), distant metastasis–free survival (DMFS), progression–free survival (PFS), and overall survival (OS) rates were 79.4%, 93.2%, 69.0%, 47.0%, and 54.2%, respectively. Treatment-related late toxicities were mild and acceptable. Univariate analysis showed that N stage was significant predictor of DMFS and PFS, favoring those with N0-1 disease. There was no significant difference on LRFS, RRFS, DMFS, OS and PFS rates between patients treated with neoadjuvant chemotherapy plus concurrent chemoradiotherapy (CCRT) and patients with neoadjuvant chemotherapy plus IMRT and adjuvant chemotherapy. The long-term results of T4 NPC treated with IMRT were excellent. Distant metastasis was still the main pattern of treatment failure. Late toxicities remain common. The role of CCRT for T4 NPC need to be reconsidered in the era of IMRT. Further prospective studies are warranted.
What problem does this paper attempt to address?